Considering that an altered glycosylation and/or glycation of transferrin affects the metabolism of Fe, thus worsening anemia, the use of exclusively glucose-free dialysis solutions might be the therapy of choice for PD patients with poorly regulated anemia, which requires high doses of ESAs. This evidence concerns the gene TF and anemia.